Literature DB >> 21383653

Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation.

A Franciscus van der Meer1, Marco A E Marcus, Daniël J Touw, Johannes H Proost, Cees Neef.   

Abstract

Maximum a posteriori Bayesian (MAPB) pharmacokinetic parameter estimation is an accurate and flexible method of estimating individual pharmacokinetic parameters using individual blood concentrations and prior information. In the past decade, many studies have developed optimal sampling strategies to estimate pharmacokinetic parameters as accurately as possible using either multiple regression analysis or MAPB estimation. This has been done for many drugs, especially immunosuppressants and anticancer agents. Methods of development for optimal sampling strategies (OSS) are diverse and heterogeneous. This review provides a comprehensive overview of OSS development methodology using MAPB pharmacokinetic parameter estimation, determines the transferability of published OSSs, and compares sampling strategies determined by MAPB estimation and multiple regression analysis. OSS development has the following components: 1) prior distributions; 2) reference value determination; 3) optimal sampling time identification; and 4) validation of the OSS. Published OSSs often lack all data necessary for the OSS to be clinically transferable. MAPB estimation is similar to multiple regression analysis in terms of predictive performance but superior in flexibility.

Mesh:

Substances:

Year:  2011        PMID: 21383653     DOI: 10.1097/FTD.0b013e31820f40f8

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  26 in total

1.  A limited sampling strategy based on maximum a posteriori Bayesian estimation for a five-probe phenotyping cocktail.

Authors:  Thu Thuy Nguyen; Henri Bénech; Alain Pruvost; Natacha Lenuzza
Journal:  Eur J Clin Pharmacol       Date:  2016-01       Impact factor: 2.953

2.  Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Neonates and Young Infants.

Authors:  Bo-Hao Tang; Yue-E Wu; Chen Kou; Yu-Jie Qi; Hui Qi; Hai-Yan Xu; Stephanie Leroux; Xin Huang; Yue Zhou; Yi Zheng; Evelyne Jacqz-Aigrain; A-Dong Shen; Wei Zhao
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 3.  Clinical mycophenolic acid monitoring in liver transplant recipients.

Authors:  Hao Chen; Bing Chen
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

4.  Limited sampling strategy to predict mycophenolic acid area under the curve in pediatric patients with nephrotic syndrome: a retrospective cohort study.

Authors:  Joanna Sobiak; Matylda Resztak; Tomasz Pawiński; Paweł Żero; Danuta Ostalska-Nowicka; Jacek Zachwieja; Maria Chrzanowska
Journal:  Eur J Clin Pharmacol       Date:  2019-06-06       Impact factor: 2.953

Review 5.  Dosage individualization in children: integration of pharmacometrics in clinical practice.

Authors:  Wei Zhao; Stéphanie Leroux; Evelyne Jacqz-Aigrain
Journal:  World J Pediatr       Date:  2014-08-15       Impact factor: 2.764

6.  Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.

Authors:  Wei Zhao; Massimo Cella; Oscar Della Pasqua; David Burger; Evelyne Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

7.  The impact of tacrolimus exposure on extrarenal adverse effects in adult renal transplant recipients.

Authors:  Olivia Campagne; Donald E Mager; Daniel Brazeau; Rocco C Venuto; Kathleen M Tornatore
Journal:  Br J Clin Pharmacol       Date:  2019-01-04       Impact factor: 4.335

Review 8.  How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

Review 9.  Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?

Authors:  Emily Brooks; Susan E Tett; Nicole M Isbel; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

10.  Limited sampling strategy using Bayesian estimation for estimating individual exposure of the once-daily prolonged-release formulation of tacrolimus in kidney transplant children.

Authors:  Wei Zhao; Anne Maisin; Véronique Baudouin; May Fakhoury; Thomas Storme; Georges Deschênes; Evelyne Jacqz-Aigrain
Journal:  Eur J Clin Pharmacol       Date:  2012-12-04       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.